Navigation Links
In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells

Pre-Clinical Results Demonstrate Potential of ONCONASE for Treatment of Neuroblastoma

BLOOMFIELD, N.J., June 27, 2007 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that new data show ONCONASE, the company's lead drug candidate, is active against naive and chemoresistant neuroblastoma cells.

The pre-clinical in vitro and in vivo data published in Cancer Letters (2007; Vol. 250, Issue 1: 107-116) through a collaboration between Alfacell and Martin Michaelis, M.D., Ph.D., at the Institute of Medicinal Virology at Johann Wolfgang University of Frankfurt, were also recently presented in Germany.

Conclusions from the studies presented indicate that ONCONASE inhibits neuroblastoma cell growth and induces caspase-independent cell death in neuroblastoma cells independently of P-gp expression or p53 status, which has been shown to contribute to multi-drug resistance in neuroblastoma as well as most other human cancers. Transmission electronic microscope investigations suggest that ONCONASE induces a process in neuroblastoma cells called autophagy (the digestion of cellular constituents by enzymes of the same cell), which leads to apoptosis (programmed cell death). Anti-tumor activity of ONCONASE against drug-sensitive and chemoresistant neuroblastoma xenografts was confirmed in animals.

"The data speak to the broad potential application for ONCONASE in various types of cancer other than the gateway indication for mesothelioma," said Kuslima Shogen, Alfacell's chairman and chief executive officer. "We now have an even better understanding of the mechanism of action that ONCONASE utilizes in overcoming multiple drug resistance in various tumor types."

Neuroblastoma is a cancer that forms in the nerve tissue. It is the most common cancer in infants, and the fourth most common type of cancer in children. Neurons (nerve cells) are the main components of the brain and spinal cord an
'"/>




Page: 1 2 3

Related medicine technology :

1. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
2. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. ANA380 Exhibits Activity In Vitro Against Multiple Clinically Relevant Hepatitis B Virus Mutants
6. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
7. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
8. Researchers Identify Intracellular Pathway of Alfacells Onconase
9. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
10. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
11. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
Post Your Comments:
(Date:5/17/2013)... 2013 Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ... developing new, patent-pending technologies poised to redefine how consumers receive ... hold a business update teleconference and webcast for shareholders and ... at 4:30 PM ET. Fuse Science, Inc. ... call and will be joined by Rubin Hanan ...
(Date:5/17/2013)... 17, 2013  Atossa Genetics, Inc. (NASDAQ: ATOS ... Kyle Guse , Chief Financial Officer & General Counsel, ... on Thursday, May 30, 2013, in New York ... The Company,s presentation is scheduled to begin at 3:30 ... To access the webcast, go to www.atossagenetics.com . ...
(Date:5/17/2013)... , May 17, 2013 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... March 31, 2013, before market on Tuesday, May 28, 2013.  ... 28, 2013, at 8:00 a.m. EDT (May 28, 2013 at ... results and provide an update on recent corporate developments. ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3
... Lions Eye Institute for Transplant and Research, Inc. ... 12,000-square-foot facility in Tampa, Florida. This state-of-the-art facility ... research, study, collaboration, and clinical advancements, as well ... and meetings/events.This marks an expansion of the current ...
... announced its readiness to assist organizations in assembling, communicating, ... phase 5 classification of the Influenza A crisis. ... strong signal that a pandemic is imminent and that ... http://www.newscom.com/cgi-bin/prnh/20080701/DC26612LOGO )A world leader ...
Cached Medicine Technology:Lions Eye Institute for Transplant & Research, Inc. Launches Multi-Million Dollar, State-of-the-Art Research Institute that Will Advance the Study of Blinding Eye Diseases 2Lions Eye Institute for Transplant & Research, Inc. Launches Multi-Million Dollar, State-of-the-Art Research Institute that Will Advance the Study of Blinding Eye Diseases 3EPSScentral Responds to Pandemic Alert 2
(Date:5/19/2013)... (PRWEB) May 19, 2013 People in Minnesota ... summer. Altman Fitness is offering its 28 Day Fat Loss ... program from the comfort of their own home. The product ... purchase. More information can be accessed here: http://altmanfitness.com/28-day-fat-loss-formula/ ... to leave their houses now, but after using the 28 ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Actos ... federal litigation now underway in U.S. District Court, Western ... Order dated May 3rd, the Court has modified the ... to eight cases rather than four. The next Status ... Thursday, May 23rd. (In re: Actos Product Liability Litigation, ...
(Date:5/19/2013)... Today, Zane Benefits, Inc. published ... insurance . Zane Benefits, which provides comprehensive and ... is the leader in health care reform, ... . , According to Zane Benefits’ website, many ... the value of small business health insurance for ...
(Date:5/19/2013)... According to a new market research report "Image ... By Applications (Healthcare (Endoscopy, Radiology, Ophthalmology), Surveillance, Automobile, ... Infrared, X-Ray) And Geography" published by MarketsandMarkets, the ... in 2012 and is expected to reach $10.75 ... 3.84% from 2013 to 2018. In terms of ...
(Date:5/19/2013)... May 19, 2013 These molecular ... US, UK, Spain, Japan, Italy, Germany and France:, ... molecular diagnostics laboratory practice, as well as key ... significant market impact during the next five years. ... and biochip technologies, test formats, detection methodologies, trends ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4
... at 4:30 p.m. Eastern Time Today -, IRVINE, ... the worldwide leader in intravascular patient temperature,management therapies, today ... fourth quarter and year ended December 31, 2007., ... record $2.7 million,compared to $2.0 million in the fourth ...
... stories of QUITPLAN Services users on display, MINNEAPOLIS, ... efforts of Minnesotans who used the free, professional,counseling from ... photo exhibits in the State Capitol. The exhibits are ... in the North Corridor of State,Capitol near the Rotunda., ...
... than teens, a new study finds, , , THURSDAY, March ... cardiovascular damage in children, especially the very youngest, new ... from 2 to 14 years old, showed that environmental ... and signs of vascular injury, suggesting an increased risk ...
... ALBANY, N.Y., March 13 The following is a,statement ... The Executive Budget proposed including a $400 million Housing,Opportunity ... statewide. These funds will be used to provide needed ... need of supportive,services., The program will be administered ...
... MATK ) announced today that life,sDHA(TM), its ... and heart health, is available in the,new Berri ... from,National Foods, Australia,s No. 1 juice company. National ... Australia, packaging approximately 50,percent of all fruit juice ...
... Blue Shield Members, PITTSBURGH, March 13 ... has received a Brand Excellence Award from the ... awards honor Blue,Cross and Blue Shield companies that ... and Blue Shield Brand image., "BCBSA congratulates ...
Cached Medicine News:Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 2Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 3Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 4Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 5Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 6Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 7Health News:Alsius Corporation Reports Record Fourth Quarter and Full Year 2007 Financial Results 8Health News:ClearWay Minnesota(SM) Celebrates QUITPLAN(R) Services at the Capitol 2Health News:ClearWay Minnesota(SM) Celebrates QUITPLAN(R) Services at the Capitol 3Health News:Secondhand Smoke Hikes Tots' Risk of Heart Disease 2Health News:Secondhand Smoke Hikes Tots' Risk of Heart Disease 3Health News:Australia's Leading Juice Company Launches Juice Blend with Martek's life'sDHA(TM) 2Health News:Australia's Leading Juice Company Launches Juice Blend with Martek's life'sDHA(TM) 3Health News:Highmark Receives Prestigious Brand Excellence Award 2
... AXIOM Artis BC is ... flexible system architecture ideal for ... flexible and ergonomic architecture enables ... system configuration to focus on:, ...
The ACUSON Sequoia C512 system elevates imaging and Doppler performance through new, high-density acoustic sampling, precise control of the transmitted acoustic waveform, and new transducer technolog...
MAGNETOM Symphony, an imaging system that offers 1.5T performance and top image quality in a short bore design....
... with Tim™ (Total imaging matrix) technology ... and highest resolution at 3T. With ... advanced applications can now be translated ... with Tim is an excellent dual-purpose ...
Medicine Products: